Zuclopenthixol and melperon in the treatment of elderly patients: a double-blind, controlled, multi-centre study.
A double-blind study was carried out in 53 elderly patients in 6 geriatric nursing homes to assess the effectiveness of the neuroleptics, zuclopenthixol and melperon (flubuperone), in the relief of restlessness, aggressiveness and other such symptoms. The initial daily dose was 4 mg zuclopenthixol or 75 mg melperon, increased if necessary over the treatment period of 4 weeks. Assessments were made on entry and after 1, 2 and 4 weeks of treatment of the overall severity of illness and of individual symptoms. The results showed that there was significant improvement in the condition of patients in both treatment groups and a significant reduction in mean total as well as in the main single symptom scores. These changes were already apparent after 1 week of treatment. Although there was a tendency for faster improvement in the zuclopenthixol group, there were no significant differences between the groups in any of the parameters assessed. Side-effects were few and generally mild and transient.
D000368:Aged; D000369:Aged, 80 and over; D000374:Aggression / Q000187:drug effects; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002090:Butyrophenones / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003006:Clopenthixol / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006791:Hostility / Q000187:drug effects; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy* / Q000523:psychology; D011595:Psychomotor Agitation / Q000188:drug therapy; D011897:Random Allocation; D013892:Thioxanthenes / Q000627:therapeutic use*
D014150:Antipsychotic Agents; D002090:Butyrophenones; D013892:Thioxanthenes; C029674:clopenthixol decanoate; D003006:Clopenthixol; C008522:metylperon